Timothy J. Barberich Purchases 60,538 Shares of Verastem, Inc. (VSTM) Stock
Verastem, Inc. (NASDAQ:VSTM) Director Timothy J. Barberich bought 60,538 shares of the stock in a transaction dated Tuesday, December 5th. The shares were purchased at an average cost of $3.95 per share, for a total transaction of $239,125.10. Following the completion of the purchase, the director now owns 130,000 shares in the company, valued at $513,500. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Verastem, Inc. (NASDAQ:VSTM) traded down $0.09 during trading on Thursday, reaching $3.81. 440,100 shares of the company were exchanged, compared to its average volume of 759,097. Verastem, Inc. has a 1 year low of $1.08 and a 1 year high of $5.71. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.12 and a current ratio of 3.12.
Verastem (NASDAQ:VSTM) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.29). sell-side analysts forecast that Verastem, Inc. will post -1.74 EPS for the current year.
VSTM has been the topic of several recent analyst reports. Cantor Fitzgerald raised shares of Verastem from a “neutral” rating to an “overweight” rating and set a $2.00 target price on the stock in a research note on Wednesday, September 6th. Oppenheimer reaffirmed a “buy” rating and issued a $6.00 price target on shares of Verastem in a research note on Wednesday, September 6th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target (up from $6.50) on shares of Verastem in a research note on Thursday, September 7th. ValuEngine lowered shares of Verastem from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research raised shares of Verastem from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Verastem presently has a consensus rating of “Buy” and a consensus price target of $7.78.
COPYRIGHT VIOLATION NOTICE: “Timothy J. Barberich Purchases 60,538 Shares of Verastem, Inc. (VSTM) Stock” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/07/timothy-j-barberich-purchases-60538-shares-of-verastem-inc-vstm-stock.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.